BR112016023980A2 - anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) - Google Patents

anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)

Info

Publication number
BR112016023980A2
BR112016023980A2 BR112016023980A BR112016023980A BR112016023980A2 BR 112016023980 A2 BR112016023980 A2 BR 112016023980A2 BR 112016023980 A BR112016023980 A BR 112016023980A BR 112016023980 A BR112016023980 A BR 112016023980A BR 112016023980 A2 BR112016023980 A2 BR 112016023980A2
Authority
BR
Brazil
Prior art keywords
vnar
vegf
growth factor
vascular endothelial
endothelial growth
Prior art date
Application number
BR112016023980A
Other languages
English (en)
Inventor
Fedorovish Licea Navarro Alexei
Olguín Jiménez Araceli
Elosua Portugal Carolina
Fernando Paniagua-Solís Jorge
Teresa Mata González María
Amanda Camacho Villegas Tanya
Original Assignee
Teraclon Idf S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teraclon Idf S L filed Critical Teraclon Idf S L
Publication of BR112016023980A2 publication Critical patent/BR112016023980A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se à seleção, isolamento e purificação de proteínas que pertencem a regiões variáveis chamadas de vhnar ou vnar, originadas a partir de imunoglobulinas do tipo ignar de elasmobrânquios com capacidade de receptor de antígeno. os clones a partir dos quais as mesmas se originam são chamados de vegfvnar v32r e v19; e os anticorpos são chamados de v32r e v19. suas sequências de aminoácidos e estruturas terciárias foram elucidadas, e sua capacidade para neutralizar a atividade de fator de crescimento endotelial vascular (vegf) foi determinada. durante o desenvolvimento da invenção, essas proteínas foram otimizadas para a expressão em um modelo de produção de e.coli em nível industrial. a invenção envolve o uso desses anticorpos em geral para tratar afecções relacionadas à angiogênese ou neovascularização e, em particular, para tratar afecções oftálmicas relacionadas à neovascularização por meio de administração tópica.
BR112016023980A 2014-04-17 2014-04-17 anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) BR112016023980A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2014/070332 WO2015158937A1 (es) 2014-04-17 2014-04-17 ANTICUERPOS MONOCLONALES RECOMBINANTES vNAR NEUTRALIZANTES DEL FACTOR DE CRECIMIENTO DEL ENDOTELIO VASCULAR VEGF

Publications (1)

Publication Number Publication Date
BR112016023980A2 true BR112016023980A2 (pt) 2017-10-17

Family

ID=50877332

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016023980A BR112016023980A2 (pt) 2014-04-17 2014-04-17 anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)

Country Status (16)

Country Link
US (1) US10370442B2 (pt)
EP (1) EP3133085A1 (pt)
JP (1) JP6426198B2 (pt)
KR (1) KR20160145166A (pt)
CN (1) CN106459193A (pt)
AR (1) AR101647A1 (pt)
AU (1) AU2014391247A1 (pt)
BR (1) BR112016023980A2 (pt)
CA (1) CA2946086A1 (pt)
IL (1) IL248320A0 (pt)
MX (1) MX2016013613A (pt)
RU (1) RU2016145136A (pt)
SG (1) SG11201608659TA (pt)
TW (1) TWI547501B (pt)
UY (1) UY36082A (pt)
WO (1) WO2015158937A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102341446B1 (ko) * 2016-09-29 2021-12-21 네이처와이즈 바이오테크 & 메디칼스 코포레이션 안구 질병을 치료하는 방법
WO2018194441A1 (es) * 2017-04-21 2018-10-25 Centro De Investigación Científica Y De Educación Superior De Ensenada, Baja California Vnar con actividad anti-angiogénica en tumores sólidos de animales de compañía
CN109593117B (zh) * 2019-01-11 2021-12-31 广州领晟医疗科技有限公司 一种用于抑制血管新生的多肽cka18n及其应用
CN109776656B (zh) * 2019-01-11 2022-03-11 广州领晟医疗科技有限公司 一种用于抑制血管新生的多肽tin7n及其应用
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977071B2 (en) * 2004-06-02 2011-07-12 Adalta Pty Ltd. Binding moieties based on shark ignar domains
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
EP2344545A4 (en) * 2008-10-06 2012-10-03 Commw Scient Ind Res Org CRYSTALLINE STRUCTURE OF BETA-AMYLOID PEPTIDE
JP2012527876A (ja) * 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質
US8496933B2 (en) 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains

Also Published As

Publication number Publication date
AR101647A1 (es) 2017-01-04
WO2015158937A1 (es) 2015-10-22
EP3133085A1 (en) 2017-02-22
US10370442B2 (en) 2019-08-06
CA2946086A1 (en) 2015-10-22
JP2017513475A (ja) 2017-06-01
US20170137504A1 (en) 2017-05-18
UY36082A (es) 2015-11-30
RU2016145136A3 (pt) 2018-08-08
CN106459193A (zh) 2017-02-22
KR20160145166A (ko) 2016-12-19
AU2014391247A1 (en) 2016-12-08
TWI547501B (zh) 2016-09-01
MX2016013613A (es) 2017-02-28
SG11201608659TA (en) 2016-12-29
JP6426198B2 (ja) 2018-11-21
IL248320A0 (en) 2016-11-30
RU2016145136A (ru) 2018-05-17
TW201546090A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20181363A1 (es) Variantes optimizadas de anticuerpos anti-vegf
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
BR112016023980A2 (pt) anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
EA201990019A1 (ru) Соединения и композиции для подавления активности shp2
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
EA201790342A1 (ru) Антитела к trem2 и способы их применения
JP2014237714A5 (pt)
AR110321A1 (es) Anticuerpos antitau y métodos de uso
BR112018006579A2 (pt) anticorpos anti-humanos cd19 humanizados e métodos de uso
RU2018132044A (ru) Антитела против тау
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
JP2014221758A5 (pt)
JP2017518258A5 (pt)
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
MD3261720T2 (ro) Anticorpi anti-Tau și utilizările acestora
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
WO2015127140A3 (en) Marburg monoclonal antibodies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 2020-02-11

B350 Update of information on the portal [chapter 15.35 patent gazette]